Our Retts results must be due soon. It will be interesting how they compare with the Neuren/Acadia results.
We know we have limited side effects for our NTI164 in both Pandas Pans and ASD, so I assume we will also have limited side effects for Retts, so only a small improvement in patients should be significant.
Significant Re Rating $80 to $800m, page-12
Add NTI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.8¢ |
Change
-0.001(1.69%) |
Mkt cap ! $60.00M | |||
| Open | High | Low | Value | Volume |
| 6.0¢ | 6.0¢ | 5.8¢ | $16.67K | 280.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 344807 | 5.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.9¢ | 128477 | 2 |
View Market Depth
| Last trade - 15.53pm 03/10/2024 (20 minute delay) ? |
| NTI (ASX) Chart |